中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
CHINESE JOURNAL OF MATERNAL AND CHILD HEALTH RESEARCH
2015年
3期
568-569
,共2页
痰热清%小儿%支气管肺炎%临床疗效
痰熱清%小兒%支氣管肺炎%臨床療效
담열청%소인%지기관폐염%림상료효
Tanreqing%children%bronchial pneumonia%clinical curative effect
目的：探讨痰热清治疗小儿支气管肺炎临床效果及安全性。方法将十堰市妇幼保健院收治的54例支气管肺炎患儿随机分为研究组和对照组各27例,对照组采用抗生素联合抗病毒药物、对症治疗；研究组在对照组基础上加用痰热清静脉滴注。观察临床症状消失时间、不良反应及总有效率。结果研究组退热时间、咳嗽消失时间、咽痛消失时间及治愈时间均低于对照组,差异均具有统计学意义(t值分别为7.53、5.94、3.58、5.22,均 P<0.05)。研究组总有效率(88.89%)明显高于对照组(70.37%),差异显著(χ2=8.21,P<0.05)。两组不良反应发生率对比,无统计学差异(χ2=0.09,P>0.05)。结论痰热清治疗小儿支气管肺炎疗效优越且未增加不良反应,可迅速控制病情,降低体温,预防惊厥发生,特别适用于基层医院或门诊,对病原菌无法辨别的患儿,值得临床推广。
目的：探討痰熱清治療小兒支氣管肺炎臨床效果及安全性。方法將十堰市婦幼保健院收治的54例支氣管肺炎患兒隨機分為研究組和對照組各27例,對照組採用抗生素聯閤抗病毒藥物、對癥治療；研究組在對照組基礎上加用痰熱清靜脈滴註。觀察臨床癥狀消失時間、不良反應及總有效率。結果研究組退熱時間、咳嗽消失時間、嚥痛消失時間及治愈時間均低于對照組,差異均具有統計學意義(t值分彆為7.53、5.94、3.58、5.22,均 P<0.05)。研究組總有效率(88.89%)明顯高于對照組(70.37%),差異顯著(χ2=8.21,P<0.05)。兩組不良反應髮生率對比,無統計學差異(χ2=0.09,P>0.05)。結論痰熱清治療小兒支氣管肺炎療效優越且未增加不良反應,可迅速控製病情,降低體溫,預防驚厥髮生,特彆適用于基層醫院或門診,對病原菌無法辨彆的患兒,值得臨床推廣。
목적：탐토담열청치료소인지기관폐염림상효과급안전성。방법장십언시부유보건원수치적54례지기관폐염환인수궤분위연구조화대조조각27례,대조조채용항생소연합항병독약물、대증치료；연구조재대조조기출상가용담열청정맥적주。관찰림상증상소실시간、불량반응급총유효솔。결과연구조퇴열시간、해수소실시간、인통소실시간급치유시간균저우대조조,차이균구유통계학의의(t치분별위7.53、5.94、3.58、5.22,균 P<0.05)。연구조총유효솔(88.89%)명현고우대조조(70.37%),차이현저(χ2=8.21,P<0.05)。량조불량반응발생솔대비,무통계학차이(χ2=0.09,P>0.05)。결론담열청치료소인지기관폐염료효우월차미증가불량반응,가신속공제병정,강저체온,예방량궐발생,특별괄용우기층의원혹문진,대병원균무법변별적환인,치득림상추엄。
Objective To investigate the clinical effect and safety of Tanreqing on treatment of pediatric bronchial pneumonia. Methods Fifty-four cases of bronchial pneumonia were randomly divided into research group and control group with 27 cases in each. The control group adopted combined antiviral drugs and antibiotics symptomatic treatment,while the research group was given Tanreqing intravenous drip based on the treatment for the control group. Clinical symptoms disappearance time, adverse reactions and total effective rate were observed. Results The disappearance time for pyretolysis, cough, sore throat and fever, and cure time in the research group were shorter than the control group, and the differences were significant (t value was 7. 53, 5. 94, 3. 58 and 5. 22, respectively, all P<0. 05). The total effective rate of the research group was significantly higher than the control group (88. 89% vs 70. 37%) with significant difference (χ2 =8. 21,P <0. 05). There was no difference in the incidence of adverse reactions between two groups (χ2 =0. 09,P >0. 05). Conclusion Tanreqing for treatment of pediatric bronchial pneumonia has superior efficacy without increasing adverse reactions. It can control disease condition, lower body temperature and prevent the incidence of eclampsia, which is suitable for grass-roots hospitals or clinics. It is worthy of clinical promotion for children patients infected with undistinguished pathogens.
